|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAST4 |
Gene summary for MAST4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAST4 | Gene ID | 375449 |
| Gene name | microtubule associated serine/threonine kinase family member 4 | |
| Gene Alias | MAST4 | |
| Cytomap | 5q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | J3QT34 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 375449 | MAST4 | CA_HPV_1 | Human | Cervix | CC | 1.75e-12 | -3.15e-01 | 0.0264 |
| 375449 | MAST4 | CCI_1 | Human | Cervix | CC | 6.06e-03 | 1.15e+00 | 0.528 |
| 375449 | MAST4 | CCI_2 | Human | Cervix | CC | 3.87e-08 | 1.17e+00 | 0.5249 |
| 375449 | MAST4 | CCI_3 | Human | Cervix | CC | 2.08e-14 | 1.22e+00 | 0.516 |
| 375449 | MAST4 | AEH-subject1 | Human | Endometrium | AEH | 2.34e-19 | 6.03e-01 | -0.3059 |
| 375449 | MAST4 | AEH-subject2 | Human | Endometrium | AEH | 4.25e-10 | 5.01e-01 | -0.2525 |
| 375449 | MAST4 | AEH-subject3 | Human | Endometrium | AEH | 5.79e-19 | 6.19e-01 | -0.2576 |
| 375449 | MAST4 | AEH-subject4 | Human | Endometrium | AEH | 2.29e-10 | 5.55e-01 | -0.2657 |
| 375449 | MAST4 | AEH-subject5 | Human | Endometrium | AEH | 2.84e-52 | 1.11e+00 | -0.2953 |
| 375449 | MAST4 | EEC-subject1 | Human | Endometrium | EEC | 2.51e-13 | 5.45e-01 | -0.2682 |
| 375449 | MAST4 | EEC-subject2 | Human | Endometrium | EEC | 1.33e-31 | 7.71e-01 | -0.2607 |
| 375449 | MAST4 | EEC-subject3 | Human | Endometrium | EEC | 1.34e-05 | 3.52e-01 | -0.2525 |
| 375449 | MAST4 | EEC-subject4 | Human | Endometrium | EEC | 2.40e-16 | 5.95e-01 | -0.2571 |
| 375449 | MAST4 | EEC-subject5 | Human | Endometrium | EEC | 1.16e-09 | 4.60e-01 | -0.249 |
| 375449 | MAST4 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.49e-03 | 2.04e-01 | -0.1869 |
| 375449 | MAST4 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 9.39e-03 | 1.71e-01 | -0.1875 |
| 375449 | MAST4 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.95e-03 | 6.87e-02 | -0.1883 |
| 375449 | MAST4 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.58e-02 | 2.12e-01 | -0.1934 |
| 375449 | MAST4 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 9.43e-09 | 1.11e-01 | -0.1917 |
| 375449 | MAST4 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.26e-06 | 1.21e-01 | -0.1916 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00181057 | Cervix | CC | peptidyl-serine phosphorylation | 63/2311 | 315/18723 | 6.65e-05 | 9.47e-04 | 63 |
| GO:00182096 | Cervix | CC | peptidyl-serine modification | 66/2311 | 338/18723 | 9.58e-05 | 1.25e-03 | 66 |
| GO:00181058 | Endometrium | AEH | peptidyl-serine phosphorylation | 50/2100 | 315/18723 | 7.20e-03 | 4.13e-02 | 50 |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
| GO:00181055 | Liver | NAFLD | peptidyl-serine phosphorylation | 63/1882 | 315/18723 | 7.45e-08 | 6.60e-06 | 63 |
| GO:00182094 | Liver | NAFLD | peptidyl-serine modification | 64/1882 | 338/18723 | 4.65e-07 | 2.89e-05 | 64 |
| GO:001810511 | Liver | HCC | peptidyl-serine phosphorylation | 169/7958 | 315/18723 | 3.86e-05 | 3.81e-04 | 169 |
| GO:001820911 | Liver | HCC | peptidyl-serine modification | 177/7958 | 338/18723 | 1.45e-04 | 1.17e-03 | 177 |
| GO:00181056 | Lung | IAC | peptidyl-serine phosphorylation | 69/2061 | 315/18723 | 1.48e-08 | 1.87e-06 | 69 |
| GO:00182095 | Lung | IAC | peptidyl-serine modification | 70/2061 | 338/18723 | 1.23e-07 | 1.10e-05 | 70 |
| GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
| GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
| GO:001810521 | Lung | MIAC | peptidyl-serine phosphorylation | 37/967 | 315/18723 | 2.73e-06 | 3.12e-04 | 37 |
| GO:001820921 | Lung | MIAC | peptidyl-serine modification | 37/967 | 338/18723 | 1.38e-05 | 9.86e-04 | 37 |
| GO:00182098 | Oral cavity | OSCC | peptidyl-serine modification | 175/7305 | 338/18723 | 1.09e-06 | 1.46e-05 | 175 |
| GO:001810510 | Oral cavity | OSCC | peptidyl-serine phosphorylation | 164/7305 | 315/18723 | 1.51e-06 | 1.99e-05 | 164 |
| GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
| GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
| GO:001810522 | Oral cavity | NEOLP | peptidyl-serine phosphorylation | 70/2005 | 315/18723 | 1.97e-09 | 1.24e-07 | 70 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAST4 | SNV | Missense_Mutation | c.976N>G | p.His326Asp | p.H326D | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | ||
| MAST4 | SNV | Missense_Mutation | novel | c.6466A>C | p.Ser2156Arg | p.S2156R | protein_coding | tolerated_low_confidence(0.05) | benign(0.029) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | |
| MAST4 | SNV | Missense_Mutation | novel | c.1999N>A | p.Val667Ile | p.V667I | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| MAST4 | SNV | Missense_Mutation | c.1279N>C | p.Asp427His | p.D427H | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| MAST4 | SNV | Missense_Mutation | novel | c.4880N>T | p.Ala1627Val | p.A1627V | protein_coding | tolerated_low_confidence(0.28) | benign(0.003) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAST4 | SNV | Missense_Mutation | c.2599N>A | p.Asp867Asn | p.D867N | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| MAST4 | SNV | Missense_Mutation | c.2614N>A | p.Asp872Asn | p.D872N | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| MAST4 | SNV | Missense_Mutation | c.2416N>A | p.Asp806Asn | p.D806N | protein_coding | deleterious(0.03) | probably_damaging(0.975) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| MAST4 | SNV | Missense_Mutation | c.626N>T | p.Ser209Leu | p.S209L | protein_coding | deleterious_low_confidence(0.02) | benign(0.007) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| MAST4 | SNV | Missense_Mutation | c.1102G>A | p.Glu368Lys | p.E368K | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |